American drugmaker Regeneron's Otarmeni can restore natural hearing in children born deaf due to a genetic mutation ...
The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy. Otarmeni is indicated for the ...
If approved, Itvisma (intrathecal onasemnogene abeparvovec) will be first and only gene replacement therapy for children two ...
At AACR 2026, researchers discussed the promise and challenges of bringing AI-powered tools into cancer research and clinical ...
The European Commission will now consider the committee's positive opinions as it determines whether to grant marketing authorization to the drugs.
The US Food and Drug Administration (FDA) has approved lunsotogene parvec-cwha (Otarmeni), the first gene therapy for genetic ...
VectorCertain LLC today announced new validation results demonstrating that its SecureAgent platform successfully detected ...
Approval in severe-to-profound and profound OTOF-related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting the ...
A model for the structure of the electron is proposed, in which the electron is composed of electric tripole, i.e., a +1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results